300 related articles for article (PubMed ID: 19075655)
1. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies.
Park SB; Krishnan AV; Lin CS; Goldstein D; Friedlander M; Kiernan MC
Curr Med Chem; 2008; 15(29):3081-94. PubMed ID: 19075655
[TBL] [Abstract][Full Text] [Related]
2. Nerve excitability assessment in chemotherapy-induced neurotoxicity.
Park SB; Lin CS; Kiernan MC
J Vis Exp; 2012 Apr; (62):. PubMed ID: 22565594
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
[TBL] [Abstract][Full Text] [Related]
4. Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches.
Screnci D; McKeage MJ
J Inorg Biochem; 1999 Oct; 77(1-2):105-10. PubMed ID: 10626361
[TBL] [Abstract][Full Text] [Related]
5. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.
Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC
J Clin Oncol; 2009 Mar; 27(8):1243-9. PubMed ID: 19164207
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies.
Beijers AJ; Jongen JL; Vreugdenhil G
Neth J Med; 2012 Jan; 70(1):18-25. PubMed ID: 22271810
[TBL] [Abstract][Full Text] [Related]
7. Neurotoxicity of antineoplastic drugs: Mechanisms, susceptibility, and neuroprotective strategies.
Pellacani C; Eleftheriou G
Adv Med Sci; 2020 Sep; 65(2):265-285. PubMed ID: 32361484
[TBL] [Abstract][Full Text] [Related]
8. Platinum-induced peripheral neurotoxicity: From pathogenesis to treatment.
Staff NP; Cavaletti G; Islam B; Lustberg M; Psimaras D; Tamburin S
J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2(Suppl 2):S26-S39. PubMed ID: 31647151
[TBL] [Abstract][Full Text] [Related]
9. The pathophysiology of oxaliplatin-induced neurotoxicity.
Kiernan MC; Krishnan AV
Curr Med Chem; 2006; 13(24):2901-7. PubMed ID: 17073636
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-induced peripheral neurotoxicity: a critical analysis.
Park SB; Goldstein D; Krishnan AV; Lin CS; Friedlander ML; Cassidy J; Koltzenburg M; Kiernan MC
CA Cancer J Clin; 2013; 63(6):419-37. PubMed ID: 24590861
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy-induced peripheral neurotoxicity.
Cavaletti G; Marmiroli P
Expert Opin Drug Saf; 2004 Nov; 3(6):535-46. PubMed ID: 15500413
[TBL] [Abstract][Full Text] [Related]
12. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy.
Amara S
Ann Pharmacother; 2008 Oct; 42(10):1481-5. PubMed ID: 18698011
[TBL] [Abstract][Full Text] [Related]
13. Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview.
Chan A; Hertz DL; Morales M; Adams EJ; Gordon S; Tan CJ; Staff NP; Kamath J; Oh J; Shinde S; Pon D; Dixit N; D'Olimpio J; Dumitrescu C; Gobbo M; Kober K; Mayo S; Pang L; Subbiah I; Beutler AS; Peters KB; Loprinzi C; Lustberg MB
Support Care Cancer; 2019 Oct; 27(10):3729-3737. PubMed ID: 31363906
[TBL] [Abstract][Full Text] [Related]
14. Neurotoxicity of taxanes: symptoms and quality of life assessment.
Kuroi K; Shimozuma K
Breast Cancer; 2004; 11(1):92-9. PubMed ID: 14718800
[TBL] [Abstract][Full Text] [Related]
15. A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.
Kobrinsky B; Joseph SO; Muggia F; Liebes L; Beric A; Malankar A; Ivy P; Hochster H
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1073-8. PubMed ID: 24048674
[TBL] [Abstract][Full Text] [Related]
16. Peripheral nerve damage associated with administration of taxanes in patients with cancer.
Argyriou AA; Koltzenburg M; Polychronopoulos P; Papapetropoulos S; Kalofonos HP
Crit Rev Oncol Hematol; 2008 Jun; 66(3):218-28. PubMed ID: 18329278
[TBL] [Abstract][Full Text] [Related]
17. Taxane and epothilone-induced peripheral neurotoxicity: From pathogenesis to treatment.
Tamburin S; Park SB; Alberti P; Demichelis C; Schenone A; Argyriou AA
J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S40-S51. PubMed ID: 31647157
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a single-center retrospective case-control study.
Kus T; Aktas G; Alpak G; Kalender ME; Sevinc A; Kul S; Temizer M; Camci C
Support Care Cancer; 2016 May; 24(5):2085-2091. PubMed ID: 26546457
[TBL] [Abstract][Full Text] [Related]
19. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.
Gamelin E; Gamelin L; Bossi L; Quasthoff S
Semin Oncol; 2002 Oct; 29(5 Suppl 15):21-33. PubMed ID: 12422305
[TBL] [Abstract][Full Text] [Related]
20. Taxane induced neuropathy in patients affected by breast cancer: Literature review.
De Iuliis F; Taglieri L; Salerno G; Lanza R; Scarpa S
Crit Rev Oncol Hematol; 2015 Oct; 96(1):34-45. PubMed ID: 26004917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
